Attorney General Neronha secures $3 million for Rhode Island in new opioid settlement with eight manufacturers
Published on Thursday, July 10, 2025
Attorney General Peter F. Neronha today announced that Rhode Island will recover approximately $3 million in settlements with eight drug makers that manufactured opioid pills and worsened the nationwide opioid crisis. The defendants will pay approximately $720 million in total nationwide.
“Every dollar of the $315 million that my Office has recovered from those that created and perpetuated the opioid epidemic goes directly towards treating and preventing substance use disorder in Rhode Island,” said Attorney General Neronha. “Through our Opioid Settlement Advisory Committee, these funds are strategically allocated to organizations and agencies best equipped to help those who suffer from this disease, as well as lead the charge on prevention efforts. The good news: we are seeing real results from these efforts, from expanding the state’s in-patient and out-patient treatment capacity, to driving down overdose and overdose deaths. Three hundred and fifteen million dollars is a lot of money which can make, and has made, a huge difference. But we won’t stop until no individual, no family, suffers further from this entirely preventable disease.”
The eight defendants and settlement totals are as follows:
- Mylan (now part of Viatris): $284,447,916 paid over nine years
- Hikma: $95,818,293 paid over one to four years
- Amneal: $71,751,010 paid over 10 years
- Apotex: $63,682,369 paid in a single year
- Indivior: $38,022,450 paid over four years
- Sun: $30,992,087 paid over one to four years
- Alvogen: $18,680,162 paid in a single year
- Zydus: $14,859,220 paid in a single year
In addition to these abatement payments, several of the settlements allow states to receive free pharmaceutical products or cash in lieu of this product. Additionally, seven of the companies (not including Indivior) are prohibited from promoting or marketing opioids and opioid products, making or selling any product that contains more than 40 mg of oxycodone per pill, and putting in place a monitoring and reporting system for suspicious orders. Indivior has agreed to not manufacture or sell opioid products for the next 10 years, but it will be able to continue marketing and selling medications to treat opioid use disorder.
Today’s announcement follows a recent settlement with Purdue Pharma and its owners, the Sackler family from which Rhode Island will receive $30 million. Including this new settlement, Attorney General Neronha has obtained settlements totaling $315 million in funds and live-saving medication from companies that helped fuel the opioid epidemic. The settlement funds must be used to address the opioids epidemic in the State and will be shared between the state and the municipalities with 80% going to the general fund and 20% allocated to all of Rhode Island’s cities and town.
Last month, the Executive Office of Health and Human Services announced that Rhode Island has seen its second year of reduction in fatal overdoses, with overdose deaths declining 25% since 2022. Although we have many more challenges ahead, the progress we have made to date is directly attributable to the funding and medication this Office has secured as a result of its litigation against opioids distributors, manufacturers, and pharmacies.
To learn more about our opioid settlement efforts, please visit our website.
###